Moreover, OS from the APPLE trial of osimertinib versus gefitinib followed by osimertinib in advanced EGFR-mutant NSCLC is almost the same in both strategies (HR = 1.01; 90% CI [0.61–1.68]), with a 18-month survival probability of 84% and 82.3%, respectively [15]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.